Convatec Group PLC (FRA:2CV) Stock Price, Trades & News

Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.05
Equity-to-Asset	0.4
Debt-to-Equity	1
Debt-to-EBITDA	2.96
Interest Coverage	6.23
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.18	Distress Grey Safe
Beneish M-Score	-2.74	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	2.4
	3-Year EBITDA Growth Rate	11.3
	3-Year EPS without NRI Growth Rate	8.3
	3-Year FCF Growth Rate	24.1
	3-Year Book Growth Rate	-3.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	12.51
	Future 3-5Y Total Revenue Growth Rate Estimate	6.12

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	72.8
	9-Day RSI	63.67
	14-Day RSI	58.47
	3-1 Month Momentum %	-6.4
	6-1 Month Momentum %	-16.43
	12-1 Month Momentum %	-30.77

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.53
	Quick Ratio	0.85
	Cash Ratio	0.11
	Days Inventory	133.2
	Days Sales Outstanding	50.51
	Days Payable	81.81

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.52
	Dividend Payout Ratio	0.38
	3-Year Dividend Growth Rate	2
	Forward Dividend Yield %	2.52
	5-Year Yield-on-Cost %	3.19
	3-Year Average Share Buyback Ratio	1.5
	Shareholder Yield %	7.69

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	56.22
	Operating Margin %	15.83
	Net Margin %	7.16
	EBITDA Margin %	21.14
	FCF Margin %	11.65
	OCF Margin %	19.23
	ROE %	10.22
	ROA %	4.64
	ROIC %	8.68
	3-Year ROIIC %	-52.73
	ROC (Joel Greenblatt) %	30.14
	ROCE %	9.06
	Years of Profitability over Past 10-Year	9
	Moat Score	5
	Tariff Resilience Score	5

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	33.06
	Forward PE Ratio	14.39
	PE Ratio without NRI	16.15
	Shiller PE Ratio	58.13
	Price-to-Owner-Earnings	18.56
	PEG Ratio	2.38
	PS Ratio	2.38
	PB Ratio	3.65
	Price-to-Free-Cash-Flow	20.15
	Price-to-Operating-Cash-Flow	12.23
	EV-to-EBIT	24.35
	EV-to-Forward-EBIT	14.51
	EV-to-EBITDA	13.77
	EV-to-Forward-EBITDA	10.09
	EV-to-Revenue	2.91
	EV-to-Forward-Revenue	2.72
	EV-to-FCF	24.69
	Price-to-GF-Value	0.84
	Price-to-Projected-FCF	1.42
	Price-to-Peter-Lynch-Fair-Value	2.43
	Earnings Yield (Greenblatt) %	4.1
	FCF Yield %	5.08
	Forward Rate of Return (Yacktman) %	11.12

Financials (Next Earnings Date:2026-08-04)

Annual Quarterly TTM

FRA:2CV's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Convatec Group PLC Executives

Details

GF Value™: €2.96

FRA:2CV

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Medium warning signs with 2CV. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	2,098.244
	EPS (TTM) (€)	0.074
	Beta	0.734
	3-Year Sharpe Ratio	0.03
	3-Year Sortino Ratio	0.04
	Volatility %	27.16
	14-Day RSI	58.47
	14-Day ATR (€)	0.102922
	20-Day SMA (€)	2.327
	12-1 Month Momentum %	-30.77
	52-Week Range (€)	2.14 - 3.38
	Shares Outstanding (Mil)	1,954.45

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Convatec Group PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Convatec Group PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings conference call for 2026	2026-08-04	In 35 days
Second quarter earnings results for 2026	2026-08-04	In 35 days
General meeting for 2025	2026-05-21 13:00	2.50 (+5.93%)
Convatec trading update	2026-05-21	2.50 (+5.93%)
GBP 0.039730 Cash Dividend	2026-04-16	2.78 (+6.11%)
Guidance call for 2026	2026-04-09 13:00	2.58 (-2.27%)
Annual report for 2025	2026-03-10	2.82 (+5.22%)
Fourth quarter earnings conference call for 2025	2026-02-24 09:00	2.62 (+4.80%)
Fourth quarter earnings results for 2025	2026-02-24	2.62 (+4.80%)
GBP 0.013990 Cash Dividend	2025-08-21	2.82 (+10.16%)

Show

Entries

Convatec Group PLC Frequently Asked Questions

What is Convatec Group PLC(FRA:2CV)'s stock price today?

The current price of FRA:2CV is €2.50. The 52 week high of FRA:2CV is €3.38 and 52 week low is €2.14.

When is next earnings date of Convatec Group PLC(FRA:2CV)?

The next earnings date of Convatec Group PLC(FRA:2CV) is 2026-08-04.

Does Convatec Group PLC(FRA:2CV) pay dividends? If so, how much?

The Dividend Yield % of Convatec Group PLC(FRA:2CV) is 2.52% (As of Today), Highest Dividend Payout Ratio of Convatec Group PLC(FRA:2CV) was 0.49. The lowest was 0.08. And the median was 0.43. The Forward Dividend Yield % of Convatec Group PLC(FRA:2CV) is 2.52%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions	2026-06-09
	Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories	2026-03-16
	Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.	2026-02-09
	Stigma, Not Condition, Is the Biggest Barrier for 1 in 3 People Living With Chronic Conditions, According to New Convatec Research	2025-10-27
	Stigma, Not Condition, Is the Biggest Barrier for 1 in 3 People Living With Chronic Conditions, According to New Convatec Research	2025-10-27
	Convatec Announces Exclusive Collaboration With Largest Wound, Ostomy and Continence Professional Nursing Organisation	2025-03-31
	Convatec launches new Esteem Body™ with Leak Defense™	2024-04-15
	FDA clears first placental extracellular matrix medical device for management of second-degree burns	2023-03-02

10/Page

Articles on Convatec Group PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.